ICICI Direct: Dr. Reddy’s Q2 Review -Strong Growth Across Key Segments
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Dr. Reddy’s Laboratories Ltd.’s Q2 revenues grew 2.0% YoY to Rs 4911 crore (our estimate Rs 4564 crore) mainly due to strong growth across segments partly offset by high base effect in Q2 FY20 (divestiture of certain proprietary products).
U.S. revenues grew 28.5% YoY to Rs 1833 crore on the back of rupee depreciation and new product launches.
Domestic revenues grew 21.5% YoY to Rs 912 crore due to Wockhardt integration and Covid-19 products.
Ebitda margins expanded 144 basis points YoY to 23.5% (our estimate 22.7%) due to lower other expenses partly offset by higher raw material and staff costs.
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.